After getting their candidates back from Eli Lilly, the old Dermira team is dashing for the clinic
After getting bought out by Eli Lilly for $1 billion last year, the old Dermira team regrouped in January with their own upstart and three inflammatory disease programs licensed back from the Big Pharma. Now, the small team has $83 million more to work with.
Evommune unveiled an $83 million Series A round on Thursday morning, which will be used to push its first three candidates into the clinic. First up is IRAK4/TrkA, a small molecule that broadly inhibits innate inflammation, which CEO Luis Peña says should enter the clinic this year. The team is looking to tackle atopic dermatitis and rosacea, with the first clinical readout expected next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.